ESPR

NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Dollar change +0.15
Percentage change 15.00	%

Peers: AMGN REGN VRTX NBIX ALNY EXEL IONS PTCT MDGL NKTR

| Held by: VTI IWM VXF IWN VTWO IWO IWC PSC PRFZ ITOT

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.79	Insider Own	1.80%	Shs Outstand	196.66M	Perf Week	13.86%
Market Cap	227.93M	Forward P/E	-	EPS next Y	-0.17	Insider Trans	-1.75%	Shs Float	194.62M	Perf Month	25.19%
Enterprise Value	707.30M	PEG	-	EPS next Q	-0.14	Inst Own	57.31%	Short Float	12.39%	Perf Quarter	-18.44%
Income	-153.22M	P/S	0.88	EPS this Y	45.54%	Inst Trans	-9.90%	Short Ratio	4.70	Perf Half Y	-49.56%
Sales	259.57M	P/B	-	EPS next Y	-12.30%	ROA	-43.96%	Short Interest	24.11M	Perf YTD	-47.73%
Book/sh	-2.17	P/C	1.99	EPS next 5Y	-	ROE	-	52W High	3.94 -70.81%	Perf Year	-48.20%
Cash/sh	0.58	P/FCF	-	EPS past 3/5Y	69.04% 40.11%	ROIC	-288.75%	52W Low	0.69 66.06%	Perf 3Y	-82.44%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	61.80% 17.50%	Gross Margin	65.29%	Volatility	8.86% 7.77%	Perf 5Y	-97.55%
Dividend TTM	-	EV/Sales	2.72	EPS Y/Y TTM	17.78%	Oper. Margin	-15.40%	ATR (14)	0.08	Perf 10Y	-98.63%
Dividend Ex-Date	-	Quick Ratio	0.81	Sales Y/Y TTM	12.99%	Profit Margin	-59.03%	RSI (14)	59.66	Recom	1.88
Dividend Gr. 3/5Y	- -	Current Ratio	1.18	EPS Q/Q	-164.11%	SMA20	3.61%	Beta	0.79	Target Price	5.79
Payout	-	Debt/Eq	-	Sales Q/Q	-52.81%	SMA50	17.69%	Rel Volume	1.12	Prev Close	1.00
Employees	304	LT Debt/Eq	-	Earnings	May 06 BMO	SMA200	-33.25%	Avg Volume	5.13M	Price	1.15
IPO	Jun 26, 2013	Option/Short	Yes / Yes	EPS/Sales Surpr.	-35.66% 19.63%	Trades		Volume	5,733,647	Change	15.00%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-18-24	Initiated	Goldman	Neutral	$4
Dec-17-24	Initiated	Cantor Fitzgerald	Overweight	$8
Jun-20-24	Downgrade	BofA Securities	Neutral → Underperform	$2.50
Jan-03-24	Downgrade	BofA Securities	Buy → Neutral
Nov-20-23	Resumed	JP Morgan	Neutral
Aug-01-23	Upgrade	Northland Capital	Under Perform → Market Perform
Jun-15-23	Upgrade	BofA Securities	Underperform → Buy	$1.25 → $4
Mar-16-23	Downgrade	Northland Capital	Market Perform → Under Perform	$1
Mar-16-23	Downgrade	BofA Securities	Neutral → Underperform	$8 → $1.50
Mar-07-23	Upgrade	Credit Suisse	Underperform → Neutral	$6.50 → $7
Feb-27-23	Resumed	BofA Securities	Neutral	$8
Feb-24-23	Upgrade	Jefferies	Hold → Buy	$12
Feb-03-23	Upgrade	Morgan Stanley	Underweight → Equal-Weight	$9
Aug-03-22	Downgrade	Credit Suisse	Neutral → Underperform	$7 → $6
May-05-22	Upgrade	JP Morgan	Underweight → Neutral	$6
Mar-10-22	Initiated	H.C. Wainwright	Buy	$22
Oct-19-21	Downgrade	Credit Suisse	Outperform → Neutral	$28 → $11
Oct-14-21	Downgrade	Morgan Stanley	Equal-Weight → Underweight	$17 → $11
May-05-21	Downgrade	Stifel	Buy → Hold	$37 → $20
Apr-26-21	Resumed	Credit Suisse	Outperform	$45

Show Previous Ratings

Jul-01-25 08:06AM	Esperion Appoints Craig Thompson to Board of Directors (GlobeNewswire)
Jun-05-25 11:30AM	Why Is Esperion Therapeutics (ESPR) Up 28.6% Since Last Earnings Report? (Zacks)
Jun-02-25 08:00AM	Esperion Reaches Settlement Agreement with Second ANDA Filer Not to Market Generic Version of NEXLETOL (bempedoic acid) Prior to April 19, 2040 (GlobeNewswire) +8.10%
May-20-25 08:00AM	Esperion to Participate in Upcoming June Investor Conferences (GlobeNewswire) +5.19%
May-12-25 08:00AM	Esperion Reaches Settlement Agreement with ANDA Filer Not to Market Generic Version of NEXLETOL (bempedoic acid) Prior to April 19, 2040 (GlobeNewswire)
09:55AM	Loading…
May-09-25 09:55AM	HLS Therapeutics and Esperion partner to commercialise oral cardiovascular medicines (Pharmaceutical Technology) -10.60%
08:00AM	Esperion to Participate in H.C. Wainwright's 3rd Annual BioConnect Investor Conference (GlobeNewswire)
May-08-25 04:30PM	Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
06:32AM	HLS Therapeutics Announces Q1 2025 Financial Results (PR Newswire)
06:30AM	HLS Therapeutics partners with Esperion Therapeutics to commercialize NEXLETOL® and NEXLIZET® in Canada (PR Newswire)
06:30AM	Esperion Partners with HLS Therapeutics to Commercialize NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) in Canada (GlobeNewswire)
May-07-25 12:09PM	ESPR's Q1 Earnings Miss Estimates, Revenues Beat, Stock Down (Zacks) -10.72%
03:05AM	Esperion Therapeutics Inc (ESPR) Q1 2025 Earnings Call Highlights: Revenue Surge and Strategic ... (GuruFocus.com)
May-06-25 07:15AM	Esperion Therapeutics (ESPR) Reports Q1 Loss, Tops Revenue Estimates (Zacks) -7.10%
06:10AM	Esperion Therapeutics: Q1 Earnings Snapshot (Associated Press Finance)
06:00AM	Loading…
06:00AM	Esperion Reports First Quarter 2025 Financial Results (GlobeNewswire)
May-01-25 10:01AM	Collegium Pharmaceutical (COLL) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Apr-29-25 10:01AM	Analysts Estimate Esperion Therapeutics (ESPR) to Report a Decline in Earnings: What to Look Out for (Zacks) +5.80%
Apr-25-25 08:00AM	Esperion to Participate in The Citizens Life Sciences Conference (GlobeNewswire)
Apr-24-25 08:56AM	Zacks Industry Outlook Highlights Aurinia Pharmaceuticals, Heron Therapeutics, Esperion Therapeutics, Pyxis Oncology and Plus Therapeutics (Zacks) -7.15%
08:00AM	Esperion Unveils Promising Research Supporting Lead Development Candidates for Primary Sclerosing Cholangitis (PSC) at R&D Day 2025 (GlobeNewswire)
Apr-23-25 09:32AM	5 Small Drug Stocks to Buy as Tariff-Related Uncertainty Looms (Zacks)
08:00AM	Esperion to Report First Quarter 2025 Financial Results on May 6 (GlobeNewswire)
Apr-22-25 09:35AM	Esperion Therapeutics (ESPR) Loses -51.03% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks) +9.12%
Apr-21-25 05:32PM	Esperion Therapeutics Inc (ESPR) Q4 2024 Earnings Call Highlights: Record Revenue Growth and ... (GuruFocus.com) -10.32%
Apr-10-25 08:00AM	Esperion to Host R&D Day to Highlight Cardiometabolic Pipeline Innovation and Next-Generation Therapeutics on April 24, 2025 (GlobeNewswire) -8.57%
Apr-03-25 11:30AM	Esperion Therapeutics (ESPR) Down 15.8% Since Last Earnings Report: Can It Rebound? (Zacks) -7.19%
Apr-01-25 08:00AM	Esperion Appoints Robert E. Hoffman to Board of Directors (GlobeNewswire)
Mar-26-25 07:00AM	Verrica Pharmaceuticals Appoints Noah L. Rosenberg, M.D., as Chief Medical Officer (GlobeNewswire)
Mar-24-25 08:00AM	Esperion to Participate in 24th Annual Needham Virtual Healthcare Conference (GlobeNewswire)
09:26AM	Loading…
Mar-21-25 09:26AM	ESPR to Study Bempedoic Acid in Pediatric Familial Hypercholesterolemia (Zacks)
Mar-20-25 08:00AM	Esperion Aligns with U.S. Food and Drug Administration to Initiate Phase 3 Clinical Trials of Bempedoic Acid in Pediatric Heterozygous and Homozygous Familial Hypercholesterolemia (GlobeNewswire)
Mar-04-25 11:52PM	Q4 2024 Esperion Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) +12.03% -6.78%
07:10AM	Esperion Therapeutics (ESPR) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
06:17AM	Esperion Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
06:00AM	Esperion Reports Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Mar-03-25 08:00AM	Esperion Partners with CSL Seqirus to Commercialize NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) in Australia (GlobeNewswire) -7.06%
Mar-01-25 07:24AM	Is Esperion Therapeutics, Inc. (ESPR) the Best Small Cap Pharma Stocks to Buy Now? (Insider Monkey)
Feb-25-25 10:00AM	Will Esperion Therapeutics (ESPR) Report Negative Earnings Next Week? What You Should Know (Zacks)
Feb-18-25 08:00AM	Esperion to Report Fourth Quarter and Full Year 2024 Financial Results on March 4 (GlobeNewswire)
Feb-13-25 04:30PM	Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-09-25 08:00AM	Esperion to Host Virtual Key Opinion Leader Event on Wednesday, January 22, 2025, at 11:30 a.m. ET. (GlobeNewswire)
Jan-02-25 08:00AM	Esperion to Participate in Upcoming 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-18-24 07:00AM	Esperion Strengthens Balance Sheet with Closing of Significant Refinancing Transactions (GlobeNewswire) -12.20%
Dec-13-24 06:00AM	Esperion Announces $210 Million Convertible Debt Financing (GlobeNewswire) -11.76%
Dec-12-24 08:00AM	Esperion Partners with Neopharm to Commercialize NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) in Israel (GlobeNewswire) -5.20%
Dec-02-24 08:00AM	Esperion Announces New Drug Submissions in Canada for NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) Treatments to Reduce LDL-C and Cardiovascular Risk (GlobeNewswire) +10.71%
Nov-26-24 08:00AM	Otsuka Submits New Drug Application in Japan for Bempedoic Acid in the Treatment of Hypercholesterolemia (GlobeNewswire)
Nov-21-24 08:00AM	Esperion to Participate in Upcoming Piper Sandler 36th Annual Healthcare Conference (GlobeNewswire)
Nov-18-24 10:30AM	Esperion Highlights New Exploratory Data from CLEAR Outcomes Trial Highlighting Value of NEXLETOL (bempedoic acid) in Oral Featured Science Session and Multiple Poster Presentations at AHA Scientific Sessions 2024 (GlobeNewswire)
Nov-08-24 04:15PM	Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire) +8.06% +10.53%
02:08AM	Esperion Therapeutics Inc (ESPR) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amidst ... (GuruFocus.com)
Nov-07-24 07:10AM	Esperion Therapeutics (ESPR) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
06:08AM	Esperion Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
06:00AM	Esperion Reports Third Quarter 2024 Financial Results and Provides a Business Update (GlobeNewswire)
Nov-04-24 08:00AM	Esperion to Participate in Upcoming Jefferies London Healthcare Conference (GlobeNewswire)
Oct-31-24 10:01AM	Esperion Therapeutics (ESPR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
08:00AM	Esperion Announces a Featured Presentation in the Late Breaker/Featured Science Track and Three Poster Presentations Accepted for the 2024 American Heart Association (AHA) Scientific Sessions (GlobeNewswire)
Oct-24-24 08:00AM	Esperion to Report Third Quarter 2024 Financial Results on November 7 (GlobeNewswire)
Oct-17-24 07:02PM	Millennium Management LLC's Strategic Reduction in Esperion Therapeutics Inc Holdings (GuruFocus.com)
Oct-03-24 04:56AM	Is Esperion Therapeutics, Inc. (ESPR) the Best NASDAQ Stock Under $5? (Insider Monkey) +7.69%
Oct-02-24 08:00AM	Esperion EU Partner Reports Final Real-World Results from MILOS German Cohort Demonstrating Strong Increase in LDL-C Goal Achievement With Addition of Bempedoic Acid (GlobeNewswire) +13.04%
Sep-25-24 04:30PM	Esperion Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-11-24 11:30AM	Why Is Esperion Therapeutics (ESPR) Down 3.9% Since Last Earnings Report? (Zacks)
Sep-05-24 08:00AM	Esperion to Participate in Upcoming 2024 Cantor Global Healthcare Conference (GlobeNewswire) -5.49%
Sep-03-24 08:00AM	Esperion Secures Additional Commercial and Medicare Formulary Coverage for NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) (GlobeNewswire)
Aug-26-24 08:00AM	Esperion to Participate in Upcoming H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire)
Aug-13-24 01:06AM	Q2 2024 Esperion Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-12-24 11:44AM	Esperion's (ESPR) Q2 Loss Narrows, Revenues Soar Year Over Year (Zacks) -8.91%
07:10AM	Esperion Therapeutics (ESPR) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
06:09AM	Esperion Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
06:00AM	Esperion Reports Second Quarter 2024 Financial Results and Provides a Business Update (GlobeNewswire)
Aug-07-24 04:30PM	Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-05-24 10:00AM	Esperion Therapeutics (ESPR) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Jul-25-24 08:00AM	Esperion to Report Second Quarter 2024 Financial Results on August 12 (GlobeNewswire)
Jul-24-24 08:00AM	Esperion to Participate in Upcoming BTIG Biotech Conference (GlobeNewswire)
Jul-16-24 08:00AM	New Digital First Marketing Campaign from Esperion Alerts Patients with Uncontrolled LDL Cholesterol to the Lipid Lurkers Inside Their Arteries (GlobeNewswire) +9.20%
Jun-28-24 07:49AM	PTC faces another Duchenne drug rejection; Coherus sells Humira biosimilar (BioPharma Dive)
07:00AM	Esperion Announces Monetization of European Royalties and Concurrent Payoff and Termination of Existing Revenue Interest Facility (GlobeNewswire)
Jun-13-24 02:31PM	Stocks to Buy: 3 Biotech Bargains Delivering Breakthroughs on a Budget (InvestorPlace)
Jun-11-24 10:00AM	3 Penny Stocks to Buy if You Want to Spend Less and Earn More (InvestorPlace)
Jun-06-24 11:31AM	Why Is Esperion Therapeutics (ESPR) Up 14.2% Since Last Earnings Report? (Zacks) +6.01%
May-23-24 12:11PM	Esperion's (ESPR) Drugs Get EU Nod for Lowering Heart Risk (Zacks) -5.46%
09:00AM	Esperion to Participate in Upcoming June Investor Conferences (GlobeNewswire)
May-22-24 08:00AM	First-In-Class Cholesterol-Lowering Treatment NILEMDO (NEXLETOL in the U.S.) and Its Combination with Ezetimibe, NUSTENDI (NEXLIZET in the U.S.), Approved In Europe To Treat Hypercholesterolemia and Significantly Reduce Cardiovascular Risk (GlobeNewswire)
May-20-24 10:30AM	Esperion Therapeutics Says Primary Endpoint Achieved in Hypercholesterolemia Treatment Phase 3 Trial; Shares Rise (MT Newswires) +5.08%
06:00AM	Bempedoic Acid Met Primary Endpoint of Phase 3 Trial in Japan for the Treatment for Hypercholesterolemia (GlobeNewswire)
May-14-24 08:00AM	Esperion Receives Five Year Patent Extension for Bempedoic Acid, Contained in NEXLETOL and NEXLIZET (GlobeNewswire)
May-10-24 04:00PM	Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
May-08-24 12:20PM	Esperion (ESPR) Q1 Earnings Beat, Stock Up on Strong Revenues (Zacks) -13.92%
11:08AM	Esperion Therapeutics, Inc. (NASDAQ:ESPR) Q1 2024 Earnings Call Transcript (Insider Monkey)
03:04AM	Esperion Therapeutics Inc (ESPR) Q1 2024 Earnings Call Transcript Highlights: Soaring Revenues ... (GuruFocus.com)
May-07-24 12:20PM	Heart Disease Drugmaker Esperion Therapeutics Reports Highest Revenue Yet, Stock Soars (Benzinga) +11.79%
10:55AM	ESPR Stock Earnings: Esperion Therapeutics Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
08:55AM	Esperion Therapeutics Inc (ESPR) Surpasses Q1 Revenue Forecasts with a 467% Increase (GuruFocus.com)
08:22AM	Why Is Esperion Therapeutics (ESPR) Stock Up 13% Today? (InvestorPlace)
07:39AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday (InvestorPlace)
07:36AM	Top Premarket Gainers (MT Newswires)
07:15AM	Esperion Therapeutics (ESPR) Q1 Earnings and Revenues Beat Estimates (Zacks)
06:11AM	Esperion Therapeutics: Q1 Earnings Snapshot (Associated Press Finance)

Esperion Therapeutics, Inc. is a pharmaceutical company, which engages in the development and commercialization of oral therapies for elevated low-density lipoprotein cholesterol. The firm offers NEXLETOL (bempedoic acid) tablets, and NEXLIZET (bempedoic acid and ezetimibe) tablets. The company was founded by Roger S. Newton, Hans Ageland, Jan O. Johansson, Anders Paul Wiklund, Michael E. Pape, David I. Scheer and Charles L. Bisgaier in May 1998 and is headquartered in Ann Arbor, MI.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Looker Benjamin	General Counsel	Jun 17 '25	Sale	1.15	6,422	7,398	401,241	Jun 18 06:45 PM
Koenig Sheldon L.	President and CEO	Jun 17 '25	Sale	1.11	30,474	33,796	1,541,488	Jun 18 06:44 PM
Halladay Benjamin	Chief Financial Officer	Jun 17 '25	Sale	1.15	7,229	8,328	474,473	Jun 18 06:44 PM
Koenig Sheldon L.	Officer	Jun 17 '25	Proposed Sale	1.11	30,474	33,793		Jun 17 04:11 PM
Halladay Benjamin	Officer	Jun 17 '25	Proposed Sale	1.15	7,229	8,329		Jun 17 03:34 PM
Looker Benjamin	Officer	Jun 17 '25	Proposed Sale	1.15	6,422	7,398		Jun 17 03:16 PM
Warren Eric	Chief Commercial Officer	Apr 17 '25	Sale	0.98	108	106	370,218	Apr 21 04:04 PM
Halladay Benjamin	Chief Financial Officer	Apr 17 '25	Sale	0.96	8	8	481,702	Apr 21 04:03 PM
Halladay Benjamin	Officer	Apr 17 '25	Proposed Sale	0.96	8	8		Apr 17 03:14 PM
Warren Eric	Officer	Apr 17 '25	Proposed Sale	0.98	108	106		Apr 17 03:08 PM
Halladay Benjamin	Chief Financial Officer	Mar 18 '25	Sale	1.48	3,535	5,242	481,710	Mar 19 04:03 PM
Warren Eric	Chief Commercial Officer	Mar 18 '25	Sale	1.49	2,433	3,618	370,326	Mar 19 04:02 PM
Koenig Sheldon L.	President and CEO	Mar 18 '25	Sale	1.50	13,047	19,623	1,571,962	Mar 19 04:02 PM
Warren Eric	Officer	Mar 18 '25	Proposed Sale	1.49	2,433	3,618		Mar 18 03:23 PM
Halladay Benjamin	Officer	Mar 18 '25	Proposed Sale	1.48	3,535	5,243		Mar 18 03:20 PM
Koenig Sheldon L.	Officer	Mar 18 '25	Proposed Sale	1.50	13,047	19,619		Mar 18 03:11 PM
Warren Eric	Chief Commercial Officer	Feb 19 '25	Sale	1.87	239	446	159,759	Feb 20 04:50 PM
Halladay Benjamin	Chief Financial Officer	Feb 19 '25	Sale	1.86	11	20	240,671	Feb 20 04:50 PM
Warren Eric	Officer	Feb 19 '25	Proposed Sale	1.87	239	446		Feb 19 03:34 PM
Halladay Benjamin	Officer	Feb 19 '25	Proposed Sale	1.86	11	20		Feb 19 03:26 PM
Halladay Benjamin	Chief Financial Officer	Jan 17 '25	Sale	2.27	9	20	240,682	Jan 21 04:38 PM
Warren Eric	Chief Commercial Officer	Jan 17 '25	Sale	2.26	123	278	159,998	Jan 21 04:37 PM
Warren Eric	Officer	Jan 17 '25	Proposed Sale	2.26	123	278		Jan 17 03:30 PM
Halladay Benjamin	Officer	Jan 17 '25	Proposed Sale	2.25	9	20		Jan 17 03:17 PM
Halladay Benjamin	Chief Financial Officer	Dec 17 '24	Sale	2.42	3,245	7,866	240,691	Dec 18 04:14 PM
Warren Eric	Chief Commercial Officer	Dec 17 '24	Sale	2.43	2,234	5,426	160,121	Dec 18 04:13 PM
Koenig Sheldon L.	President and CEO	Dec 17 '24	Sale	2.47	12,447	30,694	739,819	Dec 18 04:12 PM
Warren Eric	Officer	Dec 17 '24	Proposed Sale	2.43	2,234	5,426		Dec 17 03:46 PM
Koenig Sheldon L.	Officer	Dec 17 '24	Proposed Sale	2.47	12,447	30,698		Dec 17 03:22 PM
Halladay Benjamin	Officer	Dec 17 '24	Proposed Sale	2.42	3,245	7,865		Dec 17 03:21 PM
Warren Eric	Chief Commercial Officer	Nov 19 '24	Sale	2.17	197	427	162,355	Nov 20 04:10 PM
Warren Eric	Officer	Nov 19 '24	Proposed Sale	2.17	197	427		Nov 19 04:07 PM
Warren Eric	Chief Commercial Officer	Oct 17 '24	Sale	2.12	107	227	162,552	Oct 18 04:08 PM
Warren Eric	Officer	Oct 17 '24	Proposed Sale	2.12	107	227		Oct 17 03:25 PM
Koenig Sheldon L.	President and CEO	Sep 17 '24	Sale	1.80	14,550	26,132	752,266	Sep 18 04:12 PM
Warren Eric	Chief Commercial Officer	Sep 17 '24	Sale	1.78	2,608	4,650	162,659	Sep 18 04:11 PM
Foody Joanne M.	Officer	Sep 17 '24	Proposed Sale	1.78	3,381	6,015		Sep 17 04:02 PM
Warren Eric	Officer	Sep 17 '24	Proposed Sale	1.78	2,608	4,651		Sep 17 03:28 PM
Koenig Sheldon L.	Officer	Sep 17 '24	Proposed Sale	1.80	14,550	26,133		Sep 17 03:20 PM
Warren Eric	Chief Commercial Officer	Aug 19 '24	Sale	1.95	211	411	165,267	Aug 20 04:03 PM
Warren Eric	Officer	Aug 19 '24	Proposed Sale	1.95	211	410		Aug 19 03:50 PM
Warren Eric	Chief Commercial Officer	Jul 17 '24	Sale	2.59	108	279	165,478	Jul 19 08:30 AM
Foody Joanne M.	Chief Medical Officer	Jul 17 '24	Sale	2.60	917	2,383	272,862	Jul 19 08:29 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Esperion Therapeutics Inc

Upgrade your FINVIZ experience